🇺🇸 FDA
Pipeline program

CTX310

CRSP-CVD-400

Phase 1 small_molecule active

Quick answer

CTX310 for Cardiovascular is a Phase 1 program (small_molecule) at CRISPR Therapeutics AG with 1 ClinicalTrials.gov record(s).

Program details

Company
CRISPR Therapeutics AG
Indication
Cardiovascular
Phase
Phase 1
Modality
small_molecule
Status
active

Clinical trials